ABSTRACT
Patients with malignant diseases represent a cohort within healthcare that have some of the greatest unmet needs despite the availability of a plethora of guideline-driven disease-modulating treatments and pain and symptom management options [1,2]. Cannabinoid therapies are varied and versatile, and they are available as pharmaceuticals (Nabilone [Cesamet™], synthetic delta-9 THC [Marinol™], and THC/CBD extracts [Sativex™]), dried botanical material (marijuana), and edible organic oils infused with cannabis extracts.
